Evidence map›Paper›PMID 28161578›Full record

ArticleAntiviral research2017

Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.

Wenqian Tao, Brett L Hurst, Akhilesh Kumar Shakya, Md Jasim Uddin, Rohan S J Ingrole, Mayra Hernandez-Sanabria, Ravi P Arya, Lynn Bimler, Silke Paust, E Bart Tarbet and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antiviral research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wenqian TaoDepartment of Chemical Engineering, Texas Tech University, Lubbock, TX 79409, USA.
Brett L HurstDepartment of Animal, Dairy and Veterinary Sciences and the School of Veterinary Medicine, Utah State University, Logan, UT 84322, USA.
Akhilesh Kumar ShakyaDepartment of Chemical Engineering, Texas Tech University, Lubbock, TX 79409, USA.
Md Jasim UddinDepartment of Chemical Engineering, Texas Tech University, Lubbock, TX 79409, USA.
Rohan S J IngroleDepartment of Chemical Engineering, Texas Tech University, Lubbock, TX 79409, USA.
Mayra Hernandez-SanabriaCenter for Human Immunobiology, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, TX 77030, USA.
Ravi P AryaCenter for Human Immunobiology, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, TX 77030, USA.
Lynn BimlerCenter for Human Immunobiology, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, TX 77030, USA.
Silke PaustCenter for Human Immunobiology, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, TX 77030, USA.
E Bart TarbetDepartment of Animal, Dairy and Veterinary Sciences and the School of Veterinary Medicine, Utah State University, Logan, UT 84322, USA.
Harvinder Singh GillDepartment of Chemical Engineering, Texas Tech University, Lubbock, TX 79409, USA. Electronic address: harvinder.gill@ttu.edu.

Funding

Nanoengineered virus-mimics as templates for design of a universal influenza A vaR21AI099575 · NIAID · TEXAS TECH UNIVERSITY · PI GILL, HARVINDER SINGH · 2012 to 2013
$348k
NIAID NIH HHS HHSN272201000039CNIAID NIH HHS HHSN272201000039INIAID NIH HHS R21 AI099575
6 · The paper itself

Abstract

The extracellular domain of influenza A ion channel membrane matrix protein 2 (M2e) is considered to be a potential candidate to develop a universal influenza A vaccine. However poor immunogenicity of M2e presents a significant roadblock. We have developed a vaccine formulation comprising of the consensus M2e peptide conjugated to gold nanoparticles (AuNPs) with CpG as a soluble adjuvant (AuNP-M2e + sCpG). We demonstrate that intranasal delivery of AuNP-M2e + sCpG in mice induces lung B cell activation and robust serum anti-M2e immunoglobulin G (IgG) response, with stimulation of both IgG1 and IgG2a subtypes. Using Madin-Darby canine kidney (MDCK) cells infected with A/California/04/2009 (H1N1pdm) pandemic strain, or A/Victoria/3/75 (H3N2), or the highly pathogenic avian influenza virus A/Vietnam/1203/2004 (H5N1) as immunosorbants we further show that the antibodies generated are also capable of binding to the homotetrameric form of M2 expressed on infected cells. Lethal challenge of vaccinated mice with A/California/04/2009 (H1N1pdm) pandemic strain, A/Victoria/3/75 (H3N2), and the highly pathogenic avian influenza virus A/Vietnam/1203/2004 (H5N1) led to 100%, 92%, and 100% protection, respectively. Overall, this study helps to lay the foundation of a potential universal influenza A vaccine.

Indexed as

Cross ProtectionMetal NanoparticlesAdjuvants, ImmunologicAdministration, IntranasalAnimalsAntibodies, ViralGoldInfluenza A virusInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza A Virus, H5N1 SubtypeInfluenza VaccinesMiceMice, Inbred BALB COrthomyxoviridae InfectionsViral Matrix ProteinsAdjuvants, ImmunologicAntibodies, ViralGoldInfluenza VaccinesM2 protein, Influenza A virusViral Matrix ProteinsViroporin ProteinsAdjuvantsCpGGold nanoparticlesInfluenza vaccineIntranasal vaccinationM2eUniversal influenza vaccine

Identifiers

PMID28161578
PMCPMC5572660

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.